Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes innovative cardiovascular medicines. The company's approved product, CARDAMYST™ (etripamil) nasal spray, is available in the United States. This product is the first and only FDA-approved self-administered treatment for patients to use anywhere, anytime an attack of paroxysmal supraventricular tachycardia (PSVT) occurs. Milestone Pharmaceuticals Inc. is also pursuing marketing approval for CARDAMYST™ in regions outside the United States, either directly or through partnerships. The company is also developing etripamil for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals Inc. focuses its efforts and financial resources on three main areas: the commercialization of CARDAMYST™ (etripamil) nasal spray for PSVT, the development of etripamil for AFib-RVR, and corporate development activities aimed at increasing company value through strategic collaborations. On December 12, 2025, the FDA approved CARDAMYST™ (etripamil) nasal spray as a prescription medication for converting acute symptomatic episodes of PSVT to sinus rhythm in adults. This product became available in retail pharmacies in the first quarter of 2026. Milestone Pharmaceuticals Inc. manufactures CARDAMYST™ using a global supply chain that produces the active pharmaceutical ingredient, etripamil, formulates and assembles it into a nasal spray delivery device, and then packages the product. A third-party logistics provider distributes the product to wholesalers for delivery to retail pharmacies. The company's sales team of approximately 60 representatives aims to engage healthcare providers who are expected to treat around 500,000 patients diagnosed with PSVT in 2026. Milestone Pharmaceuticals Inc. designed the etripamil molecule and is commercializing and further developing this novel, potent, and rapid-onset calcium channel blocker as a patient-administered nasal spray to terminate episodes of transient cardiovascular conditions.